| Funding Date | Round | Amount Raised | Price per Share | Post-Money Valuation 3 | Key Investors | |
|---|---|---|---|---|---|---|
| 01/27/2026 | Series B | $134.06M | $11.94 | $272.99M | Affinity Asset Advisors, Agent Capital, Alexandria Venture Investments, Avego Management, Balyasny Asset Management, Delos Capital Partners, Eli Lilly & Company, Janus Henderson Investors, Johnson & Johnson Innovation, Pfizer Ventures Investments, Polaris Partners, Sv Health Investors | |
|
Price per Share
$ xx.xx
Shares Outstanding
11,226,399
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Affinity Asset Advisors, Agent Capital, Alexandria Venture Investments, Avego Management, Balyasny Asset Management, Delos Capital Partners, Eli Lilly & Company, Janus Henderson Investors, Johnson & Johnson Innovation, Pfizer Ventures Investments, Polaris Partners, Sv Health Investors
|
||||||
| 03/08/2022 | Series A-2 | $29.8M | $14.96 | $162.44M | Alexandria Venture Investments, Eli Lilly & Company, Johnson & Johnson Innovation, Laurion Capital Management Lp, Pfizer Ventures Investments, Sv Health Investors | |
|
Price per Share
$ xx.xx
Shares Outstanding
1,992,290
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Eli Lilly & Company, Johnson & Johnson Innovation, Laurion Capital Management Lp, Pfizer Ventures Investments, Sv Health Investors
|
||||||
| 06/22/2021 | Series A-3 | $48.31M | $14.96 | $150.36M | Alexandria Venture Investments, Eli Lilly & Company, Johnson & Johnson Innovation, Pfizer Ventures Investments, Sv Health Investors | |
|
Price per Share
$ xx.xx
Shares Outstanding
3,229,832
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Eli Lilly & Company, Johnson & Johnson Innovation, Pfizer Ventures Investments, Sv Health Investors
|
||||||
| 06/22/2021 | Series A-1 | $6.45M | $4.99 | $150.36M | Alexandria Venture Investments, Eli Lilly & Company, Johnson & Johnson Innovation, Pfizer Ventures Investments, Sv Health Investors | |
|
Price per Share
$ xx.xx
Shares Outstanding
1,293,695
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Eli Lilly & Company, Johnson & Johnson Innovation, Pfizer Ventures Investments, Sv Health Investors
|
||||||
See which private companies are preparing for the public market. Register to get full access to the latest secondary market pricing data.
| Trade Metrics | Last Funding Round | |||||||
|---|---|---|---|---|---|---|---|---|
| Company | Forge Price | Last Matched | Round | Post-Money Valuation 3 | Price Per Share | Amount Raised | ||
 | OURA | Not available | $ xx.xx | Series E | $11.36B | $53.57 | $972.43M | |
 | City Therapeutics | Not available | $ xx.xx | Series B | $571.5M | $14.63 | $99.5M | |
 | Iambic Therapeutics | Not available | $ xx.xx | Series B-4 | $671.11M | $3.26 | $32.77M | |
 | Aspen Neuroscience | Not available | $ xx.xx | Series C | $350.82M | $1.52 | $115.62M | |
 | Lycia Therapeutics | Not available | $ xx.xx | Series D | $389.03M | $2.04 | $75M | |
| Bambusa Therapeutics | Not available | $ xx.xx | Series A-2 | $532.63M | $18.73 | $33.07M | |
 | Affinia Therapeutics | Not available | $ xx.xx | Series C | $156.61M | $1.62 | $40M | |
 | Origin | Not available | $ xx.xx | Not available | -- | -- | -- | |
Track trading activity and investor momentum across thousands of private companies. Register to view last matched prices and additional transactional details.
| Company | Forge Price (6M Change) | Market Activity | Last Matched | |
|---|---|---|---|---|
 |
DataRobot | $4.21 +$3.49 (484.72%) | Limited | $xxx.xx |
 |
SambaNova Systems | $70.13 +$51.08 (268.14%) | High | $xxx.xx |
 |
SandboxAQ | $41.35 +$26.10 (171.15%) | High | $xxx.xx |
 |
Stoke Space | $119.38 +$69.46 (139.14%) | Low | $xxx.xx |
 |
Tensordyne | $29.47 +$14.97 (103.24%) | High | $xxx.xx |
| Company | Forge Price | Market Activity | Last Matched | |
|---|---|---|---|---|
 |
OpenAI | Not available | High | $xxx.xx |
 |
Anthropic | Not available | Medium | $xxx.xx |
 |
Anduril | $140.00 +$28.29 (25.32%) | High | $xxx.xx |
 |
Databricks | $268.50 +$72.19 (36.77%) | High | $xxx.xx |
 |
Perplexity | $60.00 -$9.54 (13.72%) | High | $xxx.xx |
Updated on: Oct 15, 2026
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.
The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.
Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.
